Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (DE:0Y2)
BERLIN:0Y2
Holding DE:0Y2?
Track your performance easily
0Y2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.38 - €13.90
Previous Close€4.38
Volume0.00
Average Volume (3M)4.00
Market Cap
€96.73M
Enterprise Value€73.66M
Total Cash (Recent Filing)$31.07M
Total Debt (Recent Filing)$5.43M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 30, 2024EPS Estimate
-€0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,782,429
10 Day Avg. Volume0
30 Day Avg. Volume4
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.39
Price to Sales (P/S)1191.60
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue866.54
Enterprise Value/Gross Profit475.20
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
€17.77Price Target Upside305.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Inmune Bio News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 2 trial of XPro in early Alzheimer's disease remains on track to complete full enrollment, with results expected soon after.
Financial StabilityINmune has sufficient cash to fund operations into 2025, following successful fundraising through equity offerings.
Therapeutic PotentialThe INKmune program's potential expansion into renal cell cancer could open new therapeutic avenues and market opportunities.
Bears Say
Clinical TrialsThe company has closed enrollment in the open label extension study, which might be seen as a missed opportunity for additional data.
Financial PerformanceINmune filed its 10-K, reporting YE23 results with a net loss of ($30M).
Treatment EfficacyHistorically, mCRPC has been challenging to treat with IO reactivity, with many treatments showing promise in animal models but failing in larger studies.
---
Options Prices
Currently, No data available
---
Ownership Overview
32.96% Insiders
3.90% Mutual Funds
12.49% Other Institutional Investors
50.65% Public Companies and
Individual Investors
0Y2 FAQ
What was Inmune Bio Inc’s price range in the past 12 months?
Inmune Bio Inc lowest stock price was €4.38 and its highest was €13.90 in the past 12 months.
What is Inmune Bio Inc’s market cap?
Currently, no data Available
When is Inmune Bio Inc’s upcoming earnings report date?
Inmune Bio Inc’s upcoming earnings report date is Oct 30, 2024 which is in 34 days.
How were Inmune Bio Inc’s earnings last quarter?
Inmune Bio Inc released its earnings results on Aug 01, 2024. The company reported -€0.45 earnings per share for the quarter, beating the consensus estimate of -€0.567 by €0.117.
Is Inmune Bio Inc overvalued?
According to Wall Street analysts Inmune Bio Inc’s price is currently Undervalued.
Does Inmune Bio Inc pay dividends?
Inmune Bio Inc does not currently pay dividends.
What is Inmune Bio Inc’s EPS estimate?
Inmune Bio Inc’s EPS estimate is -€0.48.
How many shares outstanding does Inmune Bio Inc have?
Inmune Bio Inc has 22,172,451 shares outstanding.
What happened to Inmune Bio Inc’s price movement after its last earnings report?
Inmune Bio Inc reported an EPS of -€0.45 in its last earnings report, beating expectations of -€0.567. Following the earnings report the stock price went up 2.74%.
Which hedge fund is a major shareholder of Inmune Bio Inc?
Currently, no hedge funds are holding shares in DE:0Y2
---
Inmune Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.77 (305.81% Upside)
€17.77 (305.81% Upside)
Blogger Sentiment
Neutral
DE:0Y2 Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $183.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.35%
12-Months-Change
Fundamentals
Return on Equity
-86.04%
Trailing 12-Months
Asset Growth
-24.77%
Trailing 12-Months
Company Description
Inmune Bio Inc
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
0Y2 Earnings Call
Q2 2024
0:00 / 0:00
---
0Y2 Stock 12 Month Forecast
Average Price Target
€17.77
▲(305.81% Upside)
Technical Analysis
Inmune Bio
―
Adaptimmune Therapeutics
―
Anixa Biosciences
―
Cellectar Biosciences
―
Gritstone Oncology
―
Best Analysts Covering 0Y2
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-10.46%
reiterated a buy rating 10 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -10.46% per trade.
---